BOVALTO RESPI 3 SUSPENSION FOR INJECTION FOR CATTLE

Negara: Irlandia

Bahasa: Inggris

Sumber: HPRA (Health Products Regulatory Authority)

Bahan aktif:

INACTIVATED BOVINE RESPIRATORY SYNCYTIAL VIRUS, STRAIN BIO-24, INACTIVATED BOVINE PARAINFLUENZA 3 VIRUS, STRAIN BIO-23, INACTIVATED MANNHEIMIA (PASTEURELLA) HAEMOLYICA, A1 STRAIN DSM 5283

Tersedia dari:

Merial Animal Health Limited

Kode ATC:

QI02AL

INN (Nama Internasional):

INACTIVATED BOVINE RESPIRATORY SYNCYTIAL VIRUS, STRAIN BIO-24, INACTIVATED BOVINE PARAINFLUENZA 3 VIRUS, STRAIN BIO-23, INACTIVA

Dosis:

Unknown

Bentuk farmasi:

Suspension for Injection

Jenis Resep:

POM(E)

Kelompok Terapi:

Bovine

Area terapi:

Inactivated viral and inactivated bacterial vaccines

Indikasi Terapi:

Immunological - Inactivated vaccine

Status otorisasi:

Authorised

Tanggal Otorisasi:

2016-02-26

Karakteristik produk

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
BOVALTO Respi 3 suspension for injection for cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose (2 ml) contains:
ACTIVE SUBSTANCES:
Inactivated bovine respiratory syncytial virus, strain BIO-24
RP
1*
Inactivated bovine parainfluenza 3 virus, strain BIO-23
RP
1*
Inactivated_ Mannheimia haemolytica_, serotype A1 strain DSM 5283
RP
1*
* Relative potency (RP) in comparison with the reference serum
obtained after vaccination of guinea pigs with a
vaccine batch that has successfully passed the challenge test in the
target animals.
ADJUVANTS:
Aluminium hydroxide
8.0 mg
Quillaja saponin (Quil A)
0.4mg
EXCIPIENTS:
Thiomersal
0.2 mg
Formaldehyde
1.0 mg at most
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection.
Appearance: Pinkish liquid with sediment.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of cattle in the absence of maternally derived
antibodies against:
- parainfluenza 3 virus, to reduce virus excretion due to infection
- bovine respiratory syncytial virus, to reduce virus excretion due to
infection
-_ Mannheimia haemolytica_ serotype A1, to reduce clinical signs and
lung lesions.
_Onset of immunity (demonstrated by challenge):_
3 weeks after primary vaccination
_Duration of immunity (demonstrated by challenge):_
6 months after primary vaccination
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_